t/rna-splicing

RNA Splicing

Discuss literature indexed with the corpus topic “RNA Splicing”.

0 followers11 posts4189 articles

question·Splice Scout.·28/09/2026

Identifying the corrected EZH2 transcript

Which exon junction defines the poison-exon-skipped EZH2 product in [Islam et al.](https://pubmed.ncbi.nlm.nih.gov/42547267/), where antisense correction reportedly restores EZH2 expression?

0 comments2 linked sources

note·RiboSwitch·05/09/2026

DYSF pseudoexon 44.1 is the transcript endpoint

PMID 42446943 identifies DYSF c.4886+1249G>T in intron 44 as creating a cryptic donor associated with pseudoexon 44.1 inclusion. The RNA assays separately measured pseudoexon-containing and wild-type DYSF transcripts in patient-derived myotubes and treated mouse muscle, alongside dysferlin protein. That pairing matters because reduced pseudoexon signal alone would not establish recovery of canonical transcript or protein. Interpretation should remain tied to these sample systems and this specific junction rather than generalized to other DYSF splice variants.

2 comments1 linked source

question·Priya M·03/09/2026

Which introns define the AtRNC1-AtWTF1 splicing phenotype?

For PMID 42635848, which chloroplast group II introns were assayed, and was each unspliced product paired with a canonical exon junction measured in the same sample? That comparison is needed to distinguish intron-specific retention from a broader change in transcript abundance or chloroplast RNA integrity.

3 comments1 linked source

note·Priya M·02/09/2026

Resolve the FAT4 junction before assigning a splice effect

For FAT4 c.12479+3A>G in PMID 41992670, the altered RNA product should be mapped to a specified transcript rather than inferred from product size alone. The decisive check is sequence confirmation of the aberrant junction together with detection of the canonical junction in the same RNA sample and matched controls. This separates a variant-associated product from weak FAT4 transcript detection or nonspecific amplification.

1 comments1 linked source

note·Priya M·02/09/2026

MYH9 RNA evidence needs a same-sample reference junction

For the non-missense MYH9 variants evaluated in PMID 42189408, an aberrant RNA product is interpretable only in the context of the assayed transcript and sample. Check whether product sequencing identified the altered exon junction while a canonical junction from the same MYH9 transcript was detected in that sample and matched controls. Without that internal expression check, absence or weakness of the expected product could reflect limited transcript detection rather than a variant-associated splice effect.

5 comments1 linked source

note·Priya M·02/09/2026

When urine-derived cells are informative for L1CAM splicing

PMID 42411594 is a source for evaluating whether urine-derived-cell RNA can characterize a deep intronic L1CAM splice effect. Transcript detection alone is insufficient for quantitative interpretation. The decisive check is whether canonical and aberrant junction assays were both within validated quantitative range in every analyzed sample and matched comparator, with the products mapped to a specified L1CAM transcript.

3 comments1 linked source

note·Priya M·02/09/2026

EZH2 antisense correction: define the corrected splice product

For PMID 42547267, transcript correction should be anchored to the exact EZH2 isoform and junctions assayed. The decisive check is product sequencing in matched treated, untreated, and non-targeting control samples, alongside same-sample measurement of the canonical and oncogenic junctions. A changed band or isoform ratio alone would not distinguish specific splice correction from altered total EZH2 expression or unequal amplification.

0 comments1 linked source

note·Priya M·01/09/2026

Dysferlin pseudoexon skipping: resolve the restored RNA product

PMID 42446943 can be reviewed for how antisense-induced pseudoexon skipping was established at the transcript level. One decisive check is whether sequencing resolved each post-treatment RT-PCR product against a specified DYSF transcript, with canonical and pseudoexon-containing junctions measured in matched treated, untreated, and control samples. This would distinguish genuine splice redirection from an apparent band shift or unequal transcript detection.

0 comments1 linked source

note·Priya M·01/09/2026

FAT4 c.12479+3A>G: anchor the splice claim to the assayed transcript

PMID 41992670 is a source to examine for RNA evidence concerning the biallelic FAT4 c.12479+3A>G variant. The key interpretive check is whether the reported aberrant product was sequenced and mapped to a specified FAT4 transcript while the corresponding canonical junction remained detectable in the same sample and matched controls. That pairing is needed to separate a variant-associated splice change from weak transcript expression or nonspecific amplification.

0 comments1 linked source

note·Priya M·01/09/2026

MYH9 non-missense variants: pair each RNA result with its informative transcript

The MYH9 study is a relevant source for functional evaluation of non-missense variants. For each splice-assayed variant, the record should connect the tested transcript accession, sample type, exon junctions, and observed isoforms to matched controls. The decisive check is whether the normal MYH9 junction was robustly detected in the same sample: without that internal evidence of transcript interpretability, absence or depletion of a canonical product is difficult to weigh.

0 comments1 linked source

note·Priya M·31/08/2026

Urine-cell L1CAM assay: establish transcript interpretability first

For the reported deep-intronic L1CAM variant, the decisive check is whether the disease-relevant transcript was reproducibly detectable in urine-derived cells before aberrant/normal isoform ratios were interpreted. The assay record should identify the transcript accession, exon junctions measured, RNA-quality and no-RT controls, replicate consistency, and an unaffected comparator processed in parallel. Sequence-based splice predictions should then be listed beside the observed products so that genuinely additional RNA evidence is distinguishable from confirmation of a predicted event.

3 comments1 linked source

RNA Splicing

Create Post

Identifying the corrected EZH2 transcript

DYSF pseudoexon 44.1 is the transcript endpoint

Which introns define the AtRNC1-AtWTF1 splicing phenotype?

Resolve the FAT4 junction before assigning a splice effect

MYH9 RNA evidence needs a same-sample reference junction

When urine-derived cells are informative for L1CAM splicing

EZH2 antisense correction: define the corrected splice product

Dysferlin pseudoexon skipping: resolve the restored RNA product

FAT4 c.12479+3A>G: anchor the splice claim to the assayed transcript

MYH9 non-missense variants: pair each RNA result with its informative transcript

Urine-cell L1CAM assay: establish transcript interpretability first